Bhavneesh Sharma: MD, MBA in Finance - NYU Stern

Portfolio Manager at Integrity Advisors

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Using Claude Fable 5 for higher project level decisions is absolutely worth it. It thinks like a senior software engineer. #AI

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Could be a good dip buying opportunity today, Cleveland Fed Nowcast forecasts cooling June inflation numbers. #stocks #investing

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Using my own implementation of Perplexity's Search as code feature in Codex CLI and Claude code for deep research of stocks. #stocks #AI

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Fracyl Health, $GUTS: Closed at 62% gain in 3 months. Picked after the midpoint trial data. #stocks #biotech

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

New contrarian idea, Grace Therapeutics, $GRCE: starting to rebound already. 57% upside
GRCE offers a post-CRL “crisis alpha” setup where the market appears to be pricing a clinical failure that did not occur.
The FDA’s CRL was CMC-related, with no stated efficacy or safety objections to GTx-104.
GTx-104 targets a real unmet need in aneurysmal subarachnoid hemorrhage by offering IV nimodipine with better bioavailability and dosing reliability.
A favorable Type A meeting and NDA resubmission could drive rerating toward the $3–$4 range, with a scenario-weighted PT of $4 (57% upside).
Key risks are CMO remediation failure, dilution before approval, and restrictive labeling from the mortality imbalance. #biotech #stocks https://t.co/VNqsxs1pHX

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

$OTLK another contrarian winner, closed at 98 pct gain in one week, last one was $REPL at around 65 pct gain. Buy the fear. #biotech #stocks

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@grok @leo_linsky @Grok in above gaming test, opus is better in 3D games but GPT is better in zero sum games. How’s that applicable to investment research and coding. They are similar in other gaming tasks.

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

$REPL: Investors waking up to the stock today, we bought it after CRL around $2/share and closed at approx. 65% cumulative gain in a month. #biotech #stocks

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@AravSrinivas hi Aravind. See my post above. Any explanation. Big let down.

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Perplexity is diverting to cheaper Sonnet 4.6 on selecting custom sources/connectors not the model selected. See screenshots. I asked the model about its name. When I didn’t select custom connectors /sources (Scite and FMP), the model identified itself as what was selected. But on selecting custom connectors, it identified itself as sonnet 4.6, a cheaper and less powerful model than what was selected (GPT 5.5 thinking and second time Opus 4.7 thinking) but showing on bottom of respondents model selected. Does Perplexity have an explanation? This sounds like fraud and I may cancel my max plan and sue.#AI #Perplexity @AskPerplexity

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

$ARQT, Arcutis Biotherapeutics | STRONG BUY $14.50 | PT $30–32 (>100% upside) | Added more today
ZORYVE is the #1 branded non-steroidal topical across psoriasis, AD, and seborrheic dermatitis.
Q1 2026 revenue hit $105.4M (+65% YoY), ZORYVE now commands 48% branded Rx share, operating cash flow remained positive, and full-year guidance of $480–495M was reaffirmed with Q2 demand through late April already tracking 13% above Q1 levels.
The stock has been cut 35% from our initial $22 entry (on a one-time $10M Ducentis milestone that inflated the EPS miss and optically heavy 10b5-1 insider selling) while every fundamental metric, revenue growth, market share, pipeline execution, cash generation, has improved, compressing forward P/S from 5.9x to a deeply discounted 3.8x on a franchise with patent protection through 2042 and management's $2.6–3.5B peak sales target.

Five near-term catalysts are stacked: the June 29 PDUFA for pediatric psoriasis ages 2–5 (93% ensemble PoS, just 5 weeks out), infant AD sNDA already submitted, vitiligo Phase 2 readout Q4 2026, HS Phase 2 readout Q1 2027, and ARQ-234 first-in-human data in H2 2026 targeting the CD200R "white space" in IL-4/IL-13-refractory AD.

Base-case SOTP yields $18.70 (+29%), bull case $28–42 (+97–190%), with a downside floor of $10–12, producing upside/downside convexity of 5:1. Long the stock, not investment advice. #stocks #biotech

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@NoLimitGains @grok summarize this video’s key insights in 5 points from best on top

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

*Si-Bone: $SIBN: Stock rebounding after pullback: Moat in sacroiliac joint implants, Rating HOLD*

SIBN is a focused small-cap medtech growth asset: FY2025 revenue was $200.9M, Q1 2026 revenue was $52.6M, and FY2026 guide is USD230-233M, but revenue remains highly U.S.-weighted and category-concentrated.

The moat in bone implants and bone fusion is real but narrow: strongest vectors are IP, FDA 510(k) clearances, clinical evidence, physician training, and reimbursement support; weakest vectors are switching costs, network effects, and competition from posterior/ASC-friendly systems.

Valuation is the main issue: one-segment DCF/SOTP plus cash/debt bridge gives bear/base/bull values of $4.61/$12.94/$23.81 and a scenario-weighted fair value of $13.99 versus ~$14.7 stock price.

The upside case requires sustained mid-teens growth, stable ~79% gross margin, operating leverage, and FCF conversion; the bear case is that revenue growth does not convert to cash fast enough and the stock remains overvalued on EV/revenue.

Investment view: Avoid for new capital / Hold only if owned; our 12-month 52-week-high POS ensemble is ~30%, so SIBN is an interesting watchlist name but not yet a Reasonable Growth buy at the current valuation. No position, not investment advice. #biotech #stocks

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

Wave Biosciences Update, $WVE Up 7% AH after ATS AATD data update

WVE-006 data are clearly positive: 400 mg monthly reached 13.6 µM total AAT, 58.7% M-AAT, 67.7% Z-AAT reduction, with no SAEs or meaningful LFT elevations reported.

This makes me more bullish on WVE because AATD now supports a credible efficacious and safe, monthly subcutaneous, reversible RNA-editing profile, with FDA accelerated-approval feedback still expected mid-2026.

BEAM-302 still has stronger raw biomarkers, but WVE’s moat is safety, reversibility, no LNP, no permanent DNA edit, and retreatment flexibility with enough efficacy to matter clinically.

The DMD moat remains underappreciated: WVE-N531 showed 7.8% mean muscle-adjusted dystrophin, 54% exon skipping, functional benefit, no SAEs, and differentiated monthly exon-skipping potential.

Developmentally, WVE-N531 remains on track for a 2026 NDA filing for accelerated approval, so WVE is no longer just an obesity-dislocation story but an AATD + DMD regulatory catalyst story.

Long WVE, BEAM. Not investment advice.
#biotech #stocks

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@bindureddy I think they are giving older cluster only.

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@Mr_Derivatives @grok what could be likely triggers for this 15-20 pct market pullback? Discuss in detail

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

New Position, REPLIMUNE GROUP $REPL - CRISIS ALPHA LONG
$1.50 | PT $3.60 | +140% Upside
---
REPL trades at 75% of net cash ($2.00/share) after a 62% collapse on its second RP1 CRL. The market is pricing 50-60% probability of wind-down. We
think that's 2x too high.

The Setup. At $1.50, you're buying $2 of cash for $1.50 and getting a four-catalyst option portfolio for free: RP2 in uveal melanoma (48% POS, REVEAL Phase 2/3, interim Q1 2027), RP2 in HCC (interim late 2026), RP1 IGNYTE-3 confirmatory Phase 3 (26% POS, $1.20/share rNPV), and RP1 ARTACUS in transplant CSCC (60% POS, strong moat), the only dedicated program for a population with zero approved therapies and 37-48% graft rejection risk on checkpoint inhibitors. Hard floor is $1.45 (full liquidation). Downside: minimal. Each catalyst that hits re-rates the stock 2-4x.

The Runway. Post-restructuring burn drops from $75M/qtr to $33M/qtr. Cash reaches both the HCC interim (late 2026) and REVEAL transition (Q1 2027) with buffer. Baker Brothers (13.4%) and RTW (8.6%), combined 22% ownership with documented rescue PIPE track records - won't let this liquidate with credible science still in trials.

The Math. Probability-weighted PT of $3.60 assumes 50% bear / 36% base / 14% bull. Even zeroing RP1 melanoma entirely, the ex-RP1 target is ~$3 (+100%).

Key Risk. IDEAYA approval before REVEAL's interim could slow enrollment and compress regulatory receptivity to an ipi+nivo comparator. Monitor Hercules covenant status and Baker Brothers 13D filings.

Bottom line: Minimal downside, 140% upside to target, two independent binary catalysts within 12 months, trading below cash. Venture-option sizing. 7:1 convexity. #biotech #investing #stocks

Long REPL, Not investment advice.

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

@XFreeze It’s very good.

[Bhavneesh Sharma: MD, MBA in Finance - NYU Stern @bs2537]

$RVMD and $IDYA: long both. Holding. #biotech #stocks